ClinicalTrials.gg

Program

luliconazole

Also written as “Luliconazole Cream 1%”, “SKX-16 (Luliconazole 10% Solution)” and “Luliconazole Solution, 10%”.

Its studies are mostly in Onychomycosis · Tinea Pedis · Tinea, led by 4 companies.

Furthest: phase 4, since Feb 19, 20158 company-led studies, 1 open or runningNext primary completion: Sep 23, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companies30 open or runningphase 4since Feb 19, 2015Feb 19, 2015none ahead
SATO Pharmaceutical21 open or runningphase 2since Oct 15, 2026Jul 25, 2021Sep 23, 2028phase 2 · NCT07929844
Topica Pharmaceuticals20 open or runningphase 3since Sep 8, 2011Jan 4, 2010none ahead
Tinea Pharmaceuticals10 open or runningphase 2since Mar 25, 2009Mar 25, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 25, 2009First study: phase 2 study in Tinea PedisNew to Tinea PharmaceuticalsTinea Pharmaceuticals · NCT00869336 · 147 enrolled · United States
  2. Jan 4, 2010Topica Pharmaceuticals's first study: phase 2 study in OnychomycosisNew to Topica PharmaceuticalsTopica Pharmaceuticals · NCT01044381 · 24 enrolled · United States
  3. Sep 8, 2011Phase 3 study in OnychomycosisTopica Pharmaceuticals · NCT01431820 · 334 enrolled · United States
  4. Feb 19, 2015Bausch Health Companies's first study: phase 4 study in Tinea PedisNew to Bausch Health CompaniesBausch Health Companies · NCT02394340 · 20 enrolled · United States
  5. May 3, 20162 phase 4 studiesBausch Health Companies · NCT02767271, NCT02767947
  6. Jul 25, 2021SATO Pharmaceutical's first study: phase 1 study in OnychomycosisNew to SATO PharmaceuticalSATO Pharmaceutical · NCT05110638 · 19 enrolled · United States
  7. Oct 15, 2026Phase 2 study in OnychomycosisPhase 2 reachedSATO Pharmaceutical · NCT07929844 · 204 planned · United States

Ahead

  1. Sep 23, 2028Primary completion: phase 2 study in OnychomycosisSATO Pharmaceutical · NCT07929844

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07929844Onychomycosis · United States2Not yet recruitingSATO PharmaceuticalSep 23, 2028204
NCT05110638Onychomycosis · United States1CompletedSATO PharmaceuticalMay 30, 202219
NCT02767947Tinea · Dominican Republic, Honduras4CompletedBausch Health CompaniesJun 29, 201675
NCT02767271Tinea Pedis · Dominican Republic, Honduras4CompletedBausch Health CompaniesApr 27, 201630
NCT02394340Tinea Pedis · United States4CompletedBausch Health CompaniesApr 1, 201520
NCT01431820Onychomycosis · United States3CompletedTopica PharmaceuticalsJun 2014334
NCT01044381Onychomycosis · United States2CompletedTopica PharmaceuticalsMay 201124
NCT00869336Tinea Pedis · United States2CompletedTinea PharmaceuticalsSep 2009147

How it is read

Names in the registry

  • “Luliconazole Cream 1%”, 3 entries
  • “SKX-16 (Luliconazole 10% Solution)”, 2 entries
  • “Luliconazole Solution, 10%”, 2 entries
  • “Luliconazole Cream 1% - 2 wks”, 1 entry
  • “Luliconazole Cream 1% - 4 wks”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.